Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention AACR Annual Meeting, the most common co-covered peer. We currently track 1 Biotech story that mention Ziihera (zanidatamab-hrii), all published on March 18, 2026.
Last mentioned: Mar 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention AACR Annual Meeting, the most common co-covered peer. We currently track 1 Biotech story that mention Ziihera (zanidatamab-hrii), all published on March 18, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ziihera (zanidatamab-hrii). Shared-story counts are live from our verified record — not editorial picks.
Anticipated Regulatory Milestones
Potential for further regulatory filings based on ongoing Phase 3 data.
AACR Annual Meeting
Expected dates for the 2026 AACR meeting where Ziihera data will be showcased.
Presentation Announcement
Zymeworks announces multiple abstracts accepted for AACR 2026.
Zymeworks Inc. (ZYME) has announced multiple upcoming presentations for its lead asset, Ziihera (zanidatamab-hrii), at the 2026 AACR Annual Meeting. These presentations are expected to showcase the therapeutic's efficacy and safety across various HER2-expressing cancers, reinforcing its position in the competitive oncology landscape.
Ziihera (zanidatamab-hrii) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
